Stelara
Dual IL-12/23 inhibition with twelve-weekly maintenance dosing.
Stelara (ustekinumab) blocks the shared p40 subunit of interleukin-12 and interleukin-23. It has one of the longest records of any dermatological biologic, and once established it is given only every twelve weeks.
- Injection
- Route
- 12 weekly
- Interval
- 4–12 wks
- First results
- IL-12 / 23
- Target
- Weight-based dosing
- Week 0 and 4 induction
- 12-weekly maintenance
- Screening protocol
Diagnosed first, treated second.
Weight-based dosing, thorough screening and structured review make it a dependable long-term option for plaque psoriasis and psoriatic arthritis — particularly for patients who want the fewest possible clinic visits.
- 01Weight-based dosing
- 02Week 0 and 4 induction
- 0312-weekly maintenance
- 04Screening protocol
- 05Long-term review
- Moderate to severe plaque psoriasis
- Preference for very infrequent dosing
- Prior systemic therapy failure
- Stable comorbidities with clear screening
- Psoriatic arthritis with skin disease
How the treatment works
A sequence, not a single appointment — each step informs the next.
- 01
Consultation
Severity scoring, joint assessment, weight-based dose selection and comorbidity review.
- 02
Screening
Tuberculosis and hepatitis screening with baseline laboratory work.
- 03
Induction
Injections at week zero and week four to reach therapeutic levels.
- 04
Maintenance
One injection every twelve weeks with scored review at each visit.
Results measured, not promised.
What to expect
- 01Steady clearance across plaques
- 02Only four injections a year
- 03Response sustained over many years
- 04Improved joint comfort and mobility
- 05Well tolerated in long-term use
Begin with a diagnosis,
not a guess.
Share a few details and the clinic will reply with available consultation times for stelara — one-to-one with Dr. Arely.
- Response
- Within 24 hours
- Consultation
- One-to-one, 45 min
- Assessment
- Trichoscopy included
- Location
- Dr. Arely Clinic
Frequently asked
Its long half-life maintains therapeutic levels across a twelve-week interval.
Well over a decade, with extensive long-term safety and efficacy data.
Yes, switching is common and is planned to avoid a gap in disease control.
Live vaccines are avoided during treatment; inactivated vaccines are given as normal.